W. B. / Bova, G. S. -- Heparan sulfate proteoglycans and prostate cancer: a conceptual framework / Schamhart, D. H. J. / Kurth, K.-H. -- Androgen receptor mutations in prostate cancer / Klocker, H. / Culig, Z. / Hobisch, A. / Hittmair, A. / Bartsch, G. / Peterziel, H. / Cato, A. C. ¿. -- Antiandrogen binding to androgen receptors and the consequences / Furr, B. J. A. -- Expression of the MDR1 gene in prostate carcinoma / Siegsmund, M. J. / Schummer, ¿. / Steidler, A. / Greschner, M. / Köhrmann, K.-U. / Alken, P. -- Human prostate cancer progression models and therapeutic intervention / Chung, L. W. K. / Kao, C. / Sikes, R. A. / Zhau, H. E. -- Tumor angiogenesis: the VEGF signalling system is a novel target for prostate cancer therapy / Marmé, D. -- Antimetastatic approaches to therapy of prostate cancer / Heicappell, R. -- Intermittent androgen suppression: rationale and clinical experience / Gleave, M. / Bruchovsky, N. / Goldenberg, S. L. / Rennie, P. -- Resistance to drug therapy in cancer: gene therapy approaches to overcome anticancer drug resistance / Licht, Th. -- PSA RT-PCR: current status and future potential / Ellis, W. J. / Vessella, R. L. / Melchior, S. W. / Lange, P. H. -- Special aspects of PSMA and PSA RT-PCR for the detection of disseminated prostate cells / Schmidt, B. / Bendhack, M. / Ackermann, R. / Schmitz-Dräger, ¿. J. -- Molecular forms of PSA, PSA density, age-/racespecific reference ranges, and PSA velocity / Beduschi, M. C. / Beduschi, R. / Oesterling, J. E. -- Reverse transcriptase- polymerase chain reaction assays used for molecular staging of prostate cancer patients / Olsson, C. A. / Buttyan, R. -- Concluding remarks / Altwein, J. E.